Not logged inA Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)
Aroldi, Francesca; Elez, Elena; Andre, Thierry; Perkins, Geraldine; Prenen, Hans; Popovici, Vlad; Gallagher, Peter; Houlden, Jennifer; Collins, Linda; Roberts, Corran; Rolfo, Christian; Di Nicolantonio, Federica; Grayson, Margaret; Boyd, Ruth; Bettens, Karolien; Delfavero, Jurgen; Coyle, Victoria; Lawler, Mark; Khawaja, Hajrah; Laurent-Puig, Pierre; Salto-Tellez, Manuel; Maughan, Tim S.; Tabernero, Josep; Adams, Richard; Jones, Robert; Hennessy, Bryan T.; Bardelli, Alberto; Peeters, Marc; Middleton, Mark R.; Wilson, Richard H.; Van Schaeybroeck, Sandra .png)
Share.png)
SavePancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 TrialGreenhalf, William; Ghaneh, Paula; Neoptolemos, John P.; Palmer, Daniel H.; Cox, Trevor F.; Lamb, Richard F.; Garner, Elizabeth; Campbell, Fiona; Mackey, John R.; Costello, Eithne; Moore, Malcolm J.; Valle, Juan W.; McDonald, Alexander C.; Carter, Ross; Tebbutt, Niall C.; Goldstein, David; Shannon, Jennifer; Dervenis, Christos; Glimelius, Bengt; Deakin, Mark; Charnley, Richard M.; Lacaine, Francois; Scarfe, Andrew G.; Middleton, Mark R.; Anthoney, Alan; Halloran, Christopher M.; Mayerle, Julia; Olah, Attila; Jackson, Richard; Rawcliffe, Charlotte L.; Scarpa, Aldo; Bassi, Claudio; Buechler, Markus W. Share Save 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
